Drug Resistance in People With Viremia on Dolutegravir-based Antiretroviral Therapy in Sub-Saharan Africa: The DTG RESIST Study

撒哈拉以南非洲地区接受多替拉韦抗逆转录病毒疗法治疗的病毒血症患者的耐药性：DTG RESIST 研究

阅读：2
作者：Loosli,Tom,Bolton Moore,Carolyn,Buzaalirwa,Lydia,Byakwaga,Helen,Çelikağ,İpek,Chimbetete,Cleophas,Ebasone,Peter Vanes,Giandhari,Jennifer,Han,Nuri,Huwa,Jacqueline,Kasozi,Charles,Mafoua,Adolphe,Messou,Eugène,Minga,Albert,Muula,Guy,Muyindike,Winnie,Ndala,Arcel Christ Massamba,Sauermann,Mamatha,Semeere,Aggrey,Singh,Lavanya,Kouyos,Roger D,Lessells,Richard,Egger,Matthias
期刊：Clinical Infectious Diseases影响因子：
时间：2025起止号：2025 Nov 6;81(4)：e128-e131
doi：10.1093/cid/ciaf204研究方向： 微生物学

Abstract

Dolutegravir resistance is an increasing concern. An analysis of the DTG RESIST study found that among 227 integrase sequences from 7 African countries (all non-B subtypes), 59 (26.0%) had at least 1 major drug resistance mutation (primarily G118R and E138A/K/T), with 49 (21.6%) predicted to have high-level resistance to dolutegravir.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用；引用内容仅为补充信息，不代表本站立场。

2、若认为本页面引用内容涉及侵权，请及时与本站联系，我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容，需注明“来源：[生知库]”并获得授权；使用引用内容的，需自行联系原作者获得许可。

4、投稿及合作请联系：info@biocloudy.com。